Valbiotis Delivers First Order to Chinese Joint Venture

• Valbiotis delivered its first Chinese joint venture order in late October, with revenue recognized in the second half of 2026.
• The 49%-owned venture placed two orders totaling 50,000 boxes of 90 capsules across all four products in the PRO range.
• The second order is in production; revenue recognition depends on shipment by December 31.
• Chinese consumer sales are targeted by year-end through cross-border e-commerce, at retail prices significantly higher than in France.
• Registrations for three products secured in Hong Kong and Singapore pave the way for potential pharmacy distribution and online sales.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Valbiotis SA published the original content used to generate this news brief via EQS News (Ref. ID: fr_reg_2426754_en) on November 02, 2026, and is solely responsible for the information contained therein.